Efficacy and safety of tigecycline: A systematic review and meta-analysis

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 9, 2011, Pages 1963-1971

  Yahav, Dafna ^a,b   Lador, Adi ^a,b   Paul, Mical ^a,b   Leibovici, Leonard ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Antibiotics; Mortality; Severe infections

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZTREONAM PLUS VANCOMYCIN; CEFTRIAXONE PLUS METRONIDAZOLE; CILASTATIN PLUS IMIPENEM; DELAFLOXACIN; ERTAPENEM; LEVOFLOXACIN; LINEZOLID; SULTAMICILLIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ABDOMINAL INFECTION; ANEMIA; ARTERY THROMBOSIS; BACTERIAL INFECTION; BLEEDING; COMMUNITY ACQUIRED PNEUMONIA; COMPARATIVE STUDY; COMPLICATED INTRAABDOMINAL INFECTION; COMPLICATED SKIN AND SKIN STRUCTURE INFECTION; DIABETIC FOOT; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION TEST; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MICROBIOLOGICAL PARAMETERS; MORTALITY; OSTEOMYELITIS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPTIC SHOCK; SIDE EFFECT; SKIN INFECTION; SUPERINFECTION; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; VANCOMYCIN RESISTANT ENTEROCOCCUS INFECTION; VEIN THROMBOSIS; VOMITING;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CONFIDENCE INTERVALS; HUMANS; MINOCYCLINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SHOCK, SEPTIC; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 80051692552     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr242     Document Type: Review

References (59)

1. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12.
2. Pankey GA. Tigecycline. J Antimicrob Chemother 2005; 56: 470-80.
3. Bradford PA, Weaver-Sands DT, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 2005; 41 Suppl 5: S315-32.
4. Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005; 41 Suppl 5: S303-14.
5. Peterson LR. A review of tigecycline - the first glycylcycline. Int J Antimicrob Agents 2008; 32 Suppl 4: S215-22.
6. Frampton JE, Curran MP. Tigecycline. Drugs 2005; 65: 2623-35.
7. FDA. Prescribing Information For Tygacil (Tigecycline). http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021821s021lbl.pdf (8 April 2011, date last accessed).
8. FDA. FDA Drug Safety Communication: Increased Risk of Death with Tygacil (Tigecycline) Compared to Other Antibiotics Used to Treat Similar Infections. http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm (8 April 2011, date last accessed).
9. Hung WY, Kogelmanb L, Volpe G et al. Tigecycline-induced acute pancreatitis: case report and literature review. Int J Antimicrob Agents 2009; 34: 486-9.
10. Pieringer H, Schmekal B, Biesenbach G et al. Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline. Ann Hematol 2010; 89: 1063-4.
11. Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.2 (Updated September 2009). The Cochrane Collaboration, 2009. http://www.cochrane-handbook.org (8 April 2011, date last accessed).
12. Higgins JP, Thompson SG, Deeks JJ et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.
13. Falagas ME, Metaxas EI. Tigecycline for the treatment of patients with community-acquired pneumonia requiring hospitalization. Expert Rev Anti Infect Ther 2009; 7: 913-23.
14. Vasilev K, Reshedko G, Orasan R et al. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother 2008; 62: i29-40.
15. Townsend ML, Pound MW, Drew RH. Tigecycline in the treatment of complicated intra-abdominal and complicated skin and skin structure infections. Ther Clin Risk Manag 2007; 3: 1059-70.
16. Schafer JJ, Goff DA, Stevenson KB et al. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy 2007; 27: 980-7.
17. Petersen PJ, Ruzin A, Tuckman M et al. In vitro activity of tigecycline against patient isolates collected during phase 3 clinical trials for diabetic foot infections. Diagn Microbiol Infect Dis 2010; 66: 407-18.
18. Tanaseanu C, Bergallo C, Tegliax O et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis 2008; 61: 329-38.
19. Dartois N, Castaing N, Gandjini H et al. Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience. J Chemother 2008; 20: 28-35.
20. Ellis-Grosse EJ, Babinchak T, Dartois N et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41: S341-53.
21. Chuang YC, Chang CM, Aradhyax S et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin-aztreonam in the treatment of complicated skin and skin structure infections in patients from India and Taiwan. J Microbiol Immunol Infect 2011; 44: 116-24.
22. Campos M, Curcio D, Seas R et al. Tigecycline as effective as vancomycin plus aztreonam in the treatment of complicated skin and skin structure infections: experience in Latin America. Rev Chilena Infectol 2009; 26: 23-31.
23. Teras J, Gardovskis J, Vaasna T et al. Overview of tigecycline efficacy and safety in the treatment of complicated skin and skin structure infections - a European perspective. J Chemother 2008; 20: 20-7.
24. Babinchak T, Ellis-Grosse E, Dartois N et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005; 41: S354-67.
25. Fomin P, Koalov S, Cooper A et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections - the European experience. J Chemother 2008; 20: 12-9.
26. Passarell JA, Meagher AK, Liolios K et al. Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother 2008; 52: 204-10.
27. Mallick R, Sun S, Schell SR. Predictors of efficacy and health resource utilization in treatment of complicated intra-abdominal infections: evidence for pooled clinical studies comparing tigecycline with imipenem-cilastatin. Surg Infect (Larchmt) 2007; 8: 159-72.
28. Postier RG, Green SL, Klein SR et al. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004; 26: 704-14.
29. Babinchak T, Zito E, Leister H. Global study of the efficacy of tigecycline versus ceftriaxone and metronidazole for the treatment of complicated intra-abdominal infections: Study 315. In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Abstract L1-339. American Society for Microbiology, Washington, DC, USA.
30. Bergallo C, Jasovich A, Teglia O et al. 308 Study Group. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis 2009; 63: 52-61.
31. Breedt J, Teras J, Gardovskis J et al. Tigecycline 305 cSSSI Study Group. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005; 49: 4658-66.
32. Chen Z, Wu J, Zhang Y et al. Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial. BMC Infect Dis 2010; 10: 217.
33. Florescu I, Beuran M, Dimov R et al. 307 Study Group. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre,double-blind, randomized study. J Antimicrob Chemother 2008; 62: i17-28.
34. Fomin P, Beuran M, Gradauskas A et al. Three Hundred Six Study Group. Tigecycline is efficacious in the treatment of complicated intra-abdominal infections. Int J Surg 2005; 3: 35-47.
35. Freire AT, Melnyk V, Kim MJ et al. 311 Study Group. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010; 68: 140-51.
36. McGovern P, Rill D, Zito E et al. Efficacy of tigecycline versus ampicillin sulbactam or amoxicillin clavulanate to treat complicated skin and skin structure infections. Study 900. In: Abstracts of the Twentieth European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 2010. Abstract P1547. European Society of Clinical Microbiology and Infectious Disease, Basel, Switzerland.
37. Oliva ME, Rekha A, Yellin A et al. 301 Study Group. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. BMC Infect Dis 2005; 5: 88.
38. O'Riordan W, Surber J, Manos P et al. Results of a phase 2 study comparing two doses of delafloxacin to tigecycline in adults with complicated skin and skin-structure infections. In: Abstracts of the Nineteenth European Congress of Clinical Microbiology and Infectious Diseases, Helsinki, Finland, 2009. Abstract P1794. European Society of Clinical Microbiology and Infectious Disease, Basel, Switzerland.
39. Sabol MB, Cooper A, Castaing N et al. Phase 3 study comparing tigecycline (TGC) and ertapenem (ERT) in patients (pts) with diabetic foot infections (DFI) with and without osteomyelitis. In: Abstracts of the Forty-seventh Annual Meeting of the Infectious Diseases Society of America, Philadelphia, PA, 2009. Abstract LB-42.
40. Sacchidanand S, Penn RL, Embil JM et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. Int J Infect Dis 2005; 9: 251-61.
41. Tanaseanu C, Milutinovic S, Calistru PI et al. 313 Study Group. Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. BMC Pulm Med 2009; 9: 44.
42. Towfigh S, Pasternak J, Poirier A et al. A multicentre, open-label, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects with complicated intra-abdominal infections. Clin Microbiol Infect 2010; 16: 1274-81.
43. Cai Y, Wang R, Liang B et al. Effectiveness and safety of tigecycline for the treatment of infectious disease: a systematic review and meta-analysis. Antimicrob Agents Chemother 2011; 55: 1162-72.
44. Gardiner D, Dukart G, Cooper A et al. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. Clin Infect Dis 2010; 50: 229-38.
45. Burkhardt O, Rauch K, Kaever V et al. Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. Int J Antimicrob Agents 2009; 34: 101-2.
46. Conte JE Jr, Golden JA, Kelly MG et al. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 2005; 25: 523-9.
47. Ji AJ, Saunders JP, Amorusi P et al. A sensitive human bone assay for quantitation of tigecycline using LC/MS/MS. J Pharm Biomed Anal 2008; 48: 866-75.
48. Rodvold KA, Gotfried MH, Cwik M et al. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006; 58: 1221-9.
49. García-Cabrera E, Jiménez-Mejías ME, Gil Navarro MV et al. Hospitale Universitarios Virgen del Rocío. Superinfection during treatment of nosocomial infections with tigecycline. Eur J Clin Microbiol Infect Dis 2010; 29: 867-71.
50. Anthony KB, Fishman NO, Linkin DR et al. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 2008; 46: 567-70.
51. Karageorgopoulos DE, Kelesidis T, Kelesidis I et al. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 2008; 62: 45-55.
52. Gordon NC, Wareham DW. A review of clinical and microbiological outcomes following treatment of infections involving multidrugresistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 2009; 63: 775-80.
53. Alvarez-Lerma F, Blanco L, Rodríguez JA et al. Differences in the use of tigecycline between ICU patients and non-ICU patients. Rev Esp Quimioter 2010; 23: 63-71.
54. Jung B, Chanques G, Ghiba M et al. Tigecycline for treatment of severe infections in intensive care: a drug use evaluation. Ann Fr Anesth Reanim 2010; 29: 354-60.
55. Versari V, Patel G, Huprikar S. Tigecycline: a comprehensive review. In: Abstracts of the Forty-seventh Annual Meeting of the Infectious Diseases Society of America, Philadelphia, PA, 2009. Abstract LB-22.
56. Lewis JS, Echevarria K, Owens A et al. Experience with the use of tigecycline (TIG) in critically ill patients. In: Abstracts of the Forty-fifth Annual Meeting of the Infectious Diseases Society of America, San Diego, CA, 2007. Abstract 1077.
57. Swoboda S, Ober M, Hainer C et al. Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit. J Antimicrob Chemother 2008; 61: 729-33.
58. Paul M, Shani V, Muchtar E et al. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother 2010; 54: 4851-63.
59. Bourgeois FT, Murthy S, Mandl KD. Outcome reporting among drug trials registered in ClinicalTrials.gov. Ann Intern Med 2010; 153: 158-66.